{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:06:07Z","timestamp":1782846367331,"version":"3.54.5"},"reference-count":32,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The COVID-19 pandemic has caused devastating morbidity and mortality globally, and poses an unprecedented threat to economic growth. The global rollout of vaccines has been met with socioeconomic disparities, impeding the global effort in infection prevention and severity reduction. The development and evaluation of candidate vaccines against COVID-19 that overcome logistical, social, and economic challenges are highly needed. Here, a trial protocol is presented to assess the safety, tolerability, and immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 vaccine among healthy participants who were SARS-CoV-2 negative in Tanzania.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The primary objective of this study was to evaluate the safety and tolerability of the TANCoV-1.3.20 nasal SARS-CoV-2 vaccine in healthy adult participants in Tanzania. The secondary objectives included the assessment of vaccine-induced humoral and cellular immune responses, and preliminary evaluation of dose-related immunogenicity.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n TANCoV-1 is a phase 1\/2a double-blinded, randomized controlled trial conducted in the Dar es Salaam and Mbeya regions of Tanzania. A total of 150 healthy participants were planned to be recruited and randomized at a 1:1:1 ratio to receive a TANCoV-1.3.20 vaccination dose of 100 \u00b5L with or without a booster, or 200 \u00b5L without a booster. Each dose group was planned to contain an intervention arm and a control arm in a 1:1 ratio. In general, 75 participants were planned to be assigned to the experimental arm, and another 75 participants were planned to be assigned to the standard arm. Participant recruitment was expected to take 6 months, with follow-up for 6 months post vaccination. The trial has two primary end points: (1) safety, as ascertained by the incidence of adverse events, and (2) immunogenicity, which involves local, humoral, and cellular immune responses. The trial enrolled healthy individuals aged between 18 and 45 years, who provided written informed consent and met all the inclusion criteria per the protocol. The data will be analyzed using Stata (version 14; StataCorp LLC). Findings will be reported according to the CONSORT (Consolidated Standards of Reporting Trials) guidelines.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This paper describes the study protocol. Recruitment was completed in February 2024, following regulatory and ethical approvals. Safety and immunogenicity data will be analyzed after the completion of participants\u2019 follow-ups. Laboratory testing is ongoing, and data cleaning and statistical analyses are underway. Safety and immunogenicity outcomes will be analyzed after all follow-up visits and laboratory assays have been completed.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This randomized clinical trial in an African context will provide valuable data that can be used to ensure the future availability of safe, cost-effective, and environmentally accustomed effective vaccines. Furthermore, the findings of this trial will help increase public awareness and acceptance of COVID-19 vaccines, contributing to efforts to combat the COVID-19 pandemic.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/81323","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:41:42Z","timestamp":1778528502000},"page":"e81323-e81323","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1\/2a, Double-Blinded Randomized Controlled Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-6493","authenticated-orcid":false,"given":"George Peter","family":"Judicate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0001-2303","authenticated-orcid":false,"given":"Marco","family":"Missanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1391-4197","authenticated-orcid":false,"given":"Mbazi","family":"Senkoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6577-5355","authenticated-orcid":false,"given":"Emmanuel","family":"Kapesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6138-4586","authenticated-orcid":false,"given":"Nhamo","family":"Chiwerengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8518-9954","authenticated-orcid":false,"given":"Redemta","family":"Ferdinand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8155-5144","authenticated-orcid":false,"given":"Gibson","family":"Kagaruki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8862-5483","authenticated-orcid":false,"given":"Godfather","family":"Kimaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4540-5637","authenticated-orcid":false,"given":"Esther","family":"Ngadaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-5254","authenticated-orcid":false,"given":"Sokoine Lesikari","family":"Kivuyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-554X","authenticated-orcid":false,"given":"Deus","family":"Buma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6421-9030","authenticated-orcid":false,"given":"Lwitiho","family":"Sudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-4855","authenticated-orcid":false,"given":"Abisai","family":"Kisinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-0628","authenticated-orcid":false,"given":"Lucas","family":"Maganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-5682","authenticated-orcid":false,"given":"Doreen","family":"Pamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2206-5909","authenticated-orcid":false,"given":"Joel","family":"Mwakisisile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-6805","authenticated-orcid":false,"given":"Willyhelmina","family":"Olomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1575-4521","authenticated-orcid":false,"given":"Nyanda","family":"Ntinginya Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-3350","authenticated-orcid":false,"given":"Said","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5972-5985","authenticated-orcid":false,"given":"Philemon","family":"Wambura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-2684","authenticated-orcid":false,"given":"Sayoki","family":"Mfinanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-020-00135-6","article-title":"The novel coronavirus outbreak in Wuhan, China","volume":"5","author":"Zhu","journal-title":"Glob Health Res Policy"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01479-w","article-title":"From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses","volume":"21","author":"Zhu","journal-title":"Respir Res"},{"key":"R3","unstructured":"Statement on the second meeting of the international health regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV). World Health Organization. Jan 30, 2020. URL: https:\/\/www.who.int\/news-room\/detail\/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) [Accessed 15-01-2021]"},{"key":"R4","unstructured":"COVID-19 weekly epidemiological update. World Health Organization; Jul 13, 2023. URL: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/371096\/nCoV-weekly-sitrep13Jul23-eng.pdf?sequence=1 [Accessed 19-07-2023]"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhip.2020.100038","article-title":"COVID-19: unpacking the low number of cases in Africa","volume":"1","author":"Chitungo","journal-title":"Public Health Pract (Oxf)"},{"key":"R6","unstructured":"WHO COVID-19 dashboard. World Health Organization. 2023. URL: https:\/\/covid19.who.int\/region\/afro\/country\/tz [Accessed 19-07-2023]"},{"issue":"9","key":"R7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1473-3099(20)30641-1","article-title":"The origin of SARS-CoV-2","volume":"20","author":"Burki","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"R8","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1001\/jama.2020.3786","article-title":"Detection of SARS-CoV-2 in different types of clinical specimens","volume":"323","author":"Wang","journal-title":"JAMA"},{"key":"R9","unstructured":"Coronavirus disease (COVID-19). Our World in Data. 2020. URL: https:\/\/ourworldindata.org\/coronavirus [Accessed 13-05-2021]"},{"issue":"5","key":"R10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/jgs.16407","article-title":"Novel coronavirus (COVID-19) epidemic: What are the risks for older patients?","volume":"68","author":"Garnier-Crussard","journal-title":"J Am Geriatr Soc"},{"key":"R11","unstructured":"Fleischmann WR . Viral genetics. In: Baron S , editor. Medical Microbiology. 4th ed. University of Texas Medical Branch (UTMB); 1996. URL: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK8439 [Accessed 04-05-2026]"},{"key":"R12","unstructured":"Enhancing readiness for omicron (B.1.1.529): technical brief and priority actions for member states. World Health Organization; Dec 17, 2021. URL: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/20211217-global-technical-brief-and-priority-action-on-omicron_latest-2.pdf [Accessed 07-04-2026]"},{"issue":"11","key":"R13","doi-asserted-by":"publisher","first-page":"e4329","DOI":"10.1093\/cid\/ciaa1517","article-title":"Survival of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus on human skin: Importance of hand hygiene in coronavirus disease 2019 (COVID-19)","volume":"73","author":"Hirose","journal-title":"Clin Infect Dis"},{"key":"R14","unstructured":"Ventilation in buildings. Centers for Disease Control and Prevention; Mar 23, 2021. URL: https:\/\/stacks.cdc.gov\/view\/cdc\/104370 [Accessed 16-05-2021]"},{"key":"R15","unstructured":"Mask use in the context of COVID-19. World Health Organization; Dec 1, 2020. URL: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/045f4cc8-f9a2-4792-b3a6-bb2e22b42ea4\/content [Accessed 16-05-2021]"},{"key":"R16","unstructured":"Testing guidance for nursing homes. Centers for Disease Control and Prevention. Jan 7, 2021. URL: https:\/\/stacks.cdc.gov\/view\/cdc\/90726\/cdc_90726_DS1.pdf? [Accessed 16-05-2021]"},{"key":"R17","unstructured":"Preventing and managing COVID-19 across long-term care services: web annex. World Health Organization; 2020. URL: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/49e3cec7-38b7-4a50-b7eb-0dad979b1eab\/content [Accessed 16-05-2021]"},{"key":"R18","unstructured":"Draft landscape of COVID-19 candidate vaccines. World Health Organization; Dec 10, 2020. URL: https:\/\/www.who.int\/docs\/default-source\/a-future-for-children\/novel-coronavirus_landscape_covid-19.pdf [Accessed 15-05-2021]"},{"issue":"7830","key":"R19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","journal-title":"Nature New Biol"},{"key":"R20","unstructured":"Development and licensure of vaccines to prevent COVID-19: guidance for industry. U.S. Food and Drug Administration (FDA); Oct 2023. URL: https:\/\/www.fda.gov\/media\/139638\/download [Accessed 16-05-2021]"},{"key":"R21","unstructured":"WHO target product profiles for COVID-19 vaccines. World Health Organization; Apr 29, 2020. URL: https:\/\/www.who.int\/docs\/default-source\/blue-print\/who-target-product-profiles-for-covid-19-vaccines.pdf? [Accessed 16-05-2021]"},{"key":"R22","unstructured":"Vaccine manufacturing in Africa: what it takes and why it matters. Tony Blair Institute for Change. Apr 1, 2021. URL: https:\/\/institute.global\/advisory\/vaccine-manufacturing-africa-what-it-takes-and-why-it-matters [Accessed 15-05-2021]"},{"key":"R23","unstructured":"Economic Commission for Africa. Africa can take a shot at own COVID-19 vaccine. United Nations Africa Renewal. Mar 26, 2021. URL: https:\/\/africarenewal.un.org\/en\/magazine\/africa-can-take-shot-own-covid-19-vaccine [Accessed 16-05-2021]"},{"key":"R24","unstructured":"Fact sheet: explaining Operation Warp Speed. U.S. Department of Health and Human Services; 2020. URL: https:\/\/covid19.nihb.org\/wp-content\/uploads\/2020\/08\/Fact-sheet-operation-warp-speed.pdf [Accessed 05-11-2020]"},{"key":"R25","unstructured":"WHO recommendation BioNtech tozinameran\u2014COVID-19 mRNA vaccine (nucleoside modified)\u2014COMIRNATY\u00ae. World Health Organization\u2013Prequalification of Medical Products. URL: https:\/\/extranet.who.int\/prequal\/vaccines\/who-recommendation-biontech-tozinameran-covid-19-mrna-vaccine-nucleoside-modified [Accessed 15-05-2021]"},{"issue":"10","key":"R26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1099\/jgv.0.001474","article-title":"Multiple novel non-canonically transcribed sub-genomic mRNAs produced by avian coronavirus infectious bronchitis virus","volume":"101","author":"Keep","journal-title":"J Gen Virol"},{"issue":"3","key":"R27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jinf.2005.04.010","article-title":"Proposal for vaccination against SARS coronavirus using avian infectious bronchitis virus strain H from The Netherlands","volume":"51","author":"Bijlenga","journal-title":"J Infect"},{"issue":"3","key":"R28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/oxfordjournals.aje.a120901","article-title":"Neutralization of infectious bronchitis virus by human sera","volume":"88","author":"Miller","journal-title":"Am J Epidemiol"},{"issue":"1","key":"R29","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"Sekhon","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"R30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3844\/amjbsp.2010.23.31","article-title":"Comparisons of test statistics for noninferiority test for the difference between two independent binominal proportions","volume":"1","author":"Kawasaki","journal-title":"Am J Biostat"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","journal-title":"BMJ"},{"issue":"3","key":"R32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.18683\/germs.2021.1280","article-title":"The challenges to a successful COVID-19 vaccination programme in Africa","volume":"11","author":"Ayenigbara","journal-title":"Germs"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e81323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:15:06Z","timestamp":1782843306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e81323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2196\/81323","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"v15i1e81323"}}